Product Description: Efzimfotase alfa (ALXN-1850) is enzyme replacement therapy agent targeting the deficiency of tissue-nonspecific alkaline phosphatase (TNSALP). Efzimfotase alfa functions by hydrolyzing the substrates of TNSALP, reducing the concentrations of substrates such as inorganic pyrophosphate (PPi) and pyridoxal 5′-phosphate (PLP). Efzimfotase alfa is promising for research of hypophosphatasia (HPP)[1][2].
Applications: Neuroscience-Neuromodulation
Formula: N/A
References: [1]Dahir KM, et al. Medical Management of Hypophosphatasia: Review of Data on Asfotase Alfa. Curr Osteoporos Rep. 2025 Mar 18;23(1):14./[2]Dahir KM, et al. Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia. J Bone Miner Res. 2024 Sep 26;39(10):1412-1423.
CAS Number: 2746354-58-3
Molecular Weight: N/A
Research Area: Cardiovascular Disease
Target: Phosphatase
Deutsch
English
